Low-Dose Atropine Not FDA Approved: What the STAR Study Means for Today’s Myopia Control Practices cover art

Low-Dose Atropine Not FDA Approved: What the STAR Study Means for Today’s Myopia Control Practices

Low-Dose Atropine Not FDA Approved: What the STAR Study Means for Today’s Myopia Control Practices

Listen for free

View show details

About this listen

 The topic of low-dose atropine, not FDA-approved, has become one of the most important conversations in pediatric eye care this year, especially as clinicians turn to the STAR Study for clarity on atropine’s role in modern myopia control. The STAR Study is the largest and most ethnically diverse atropine study to date, evaluating 0.01% and 0.03% atropine versus placebo in more than 800 children across three countries.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.